GlaxoSmithKline's JV ViiV Healthcare says trial of injectable HIV treatment met objectives

Writer,

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

ViiV Healthcare, a GlaxoSmithKline-Pfizer joint venture, said its injectable HIV treatment had met its primary goal in a clinical trial, reducing the number of treatments needed every year, compared to an oral treatment.

'The study met its primary endpoint, showing that the long-acting regimen of cabotegravir and rilpivirine, injected every two months, was non-inferior to cabotegravir and rilpivirine administered every month at Week 48,' the company said.

'The ATLAS-2M study results mean that people living with HIV could maintain viral suppression with six total treatments per year, instead of a daily oral treatment 365 times per year, it added.

The study was designed to demonstrate the non-inferior antiviral activity and safety of cabotegravir and rilpivirine administered every eight weeks (two months) compared to every four weeks (monthly) over a 48-week treatment period in adults living with HIV-1 infection, whose viral load was suppressed and who were not resistant to cabotegravir or rilpivirine.